N/A N=47 Treatments of Mal de Debarquement Syndrome (MdDS) by Habituation of Velocity Storage
Mal de Debarquement Syndrome (MdDS)
Primary: Subjective Symptoms Self-report of Overall Severity — 5.2; 5.2; 3.2; 2.1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome
Mal de Debarquement Syndrome
Primary: Dizziness Handicap Inventory — -17.5; -3.7; -8.4; -10.1 score on a scale — p=0.0439
N/A N=10 Sensory Training for Visual Motion Sickness
Dizziness · Vertigo · Motion Sickness
Primary: Rod and Disk Test (RDT) Mean Performance — 17; 13.3; 7.8; 12.1 degrees
Phase 3 N=40 Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Meniere Disease
Primary: Number of Vertigo Episodes — 5.41; 5.03; 13.78 number of episodes — p=<0.001
N/A N=41 Effects of Lifestyle Modification on Vestibular Migraine
Vestibular Migraine
Primary: Headache Disability Inventory (HDI) — 14.3 score on a scale — p=<.0001
Phase 3 N=134 Rizatriptan for Episodic Dizziness in Vestibular Migraine
Vestibular Migraine · Migrainous Vertigo
Primary: Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild — 50; 73 Episodes — p=<0.33
Phase 2 N=40 Galcanezumab for Vestibular Migraine
Vestibular Migraine
Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale
Phase 3 N=316 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Motion Sickness
Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 11; 19; 40 Participants
N/A N=32 Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium
Vestibular Diseases · Labyrinth Diseases · Ear Diseases
Primary: Assessment of the Efficacy of the SEMD Device in Improving Vestibular Function Was Evaluated With Change in Pre Test to Post Test 1 Sensory Organization Test (SOT)…
N/A N=26 Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients
Benign Paroxysmal Positional Vertigo
Primary: Likert Scale for Satisfaction — 9; 9 units on a scale
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
N/A N=107 Sensory Integration of Auditory and Visual Cues in Diverse Contexts
Vestibular Disorder · Hearing Loss, Sensorineural
Primary: Root Mean Square Velocity Anterior-posterior [AP] in cm/s (RMSV) — 3.59; 3.30; 3.07 cm/s — p=0.005
N/A N=24 Computerized Vestibular Rehabilitation
Vestibular Diseases
Primary: Vestibulo-ocular Reflex Gain Ratio — 1.15 unitless gain ratio — p=<0.001
N/A N=6 Vestibular Rehabilitation and Otolith Dysfunction
Dizziness
Primary: Change in Static Subjective Visual Vertical (SVV) — 0.69; 0.58; 0.69; 0.89 degrees — p=0.97
N/A N=8 Postural Stability in Cervical Spinal Myelopathy
Cervical Spondylotic Myelopathy
Primary: Virtual Environment TBI System (VETS) Assessment of Static Posturography — 11; 13.0; 48.4; 19.1 Square Centimeters
N/A N=17 "Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?"
Dizziness
Primary: Modified Clinical Test of Sensory Integration for Balance (mCTSIB) — 115.98; 97.4; 110.15; 107.23 seconds — p=.640
N/A N=62 Impact of Vertigoheel® on Patients Suffering From Bilateral Vestibulopathy and Functional Dizziness
Vertigo · Functional Dizziness · Bilateral Vestibulopathy
Primary: Dizziness Handicap Inventory — -12.0; -13.2 score on a scale
Phase 2 N=24 Dalfampridine for Imbalance in Multiple Sclerosis
Multiple Sclerosis · Fatigue
Primary: Change in Automatic Postural Response (APR )Latency — 5.71; 4.58 milliseconds — p=0.51
Phase 2 N=15 Study of Lamotrigine to Treat Ménière's Disease
Meniere's Disease · Ménière's Vertigo · Vertigo, Intermittent
Primary: Change in Ménière's Vertigo Attack Frequency Between Lamotrigine and Placebo Group — 18.88; 18.00; 13.50; 4.57 Average Total Number of Vertigo Attacks — p=0.5618
N/A N=23 Recovery of Visual Acuity in People With Vestibular Deficits
Vestibular Neuronitis · Vestibular Neuronitis, Bilateral · Vestibular Schwannoma
Primary: Change in Visual Acuity During Head Movement From Baseline to Discharge — 0.198; .296 LogMAR
Phase 3 N=27 Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease
Meniere's Disease
Primary: Change in Dizziness Handicap Inventory (DHI) Questionnaire Score — 10.25; 49.6 units on a scale
Phase 3 N=366 Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Sickness
Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 22; 24; 54 Participants
N/A N=12 Pilot Project on External Vestibular Prosthesis in Chronic Subjective Dizziness
Dizziness Chronic
Primary: Degrees of Sway — 1.824; 0.746; 1.638; 0.573 degrees of sway — p=0.005
Phase 2 N=107 Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy
Acute Unilateral Vestibulopathy (AUV)
Primary: Standing Vertigo Intensity — 165.10; 155.10; 136.60 mm*day — p=0.8466
N/A N=309 Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice
Vertigo
Primary: Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE) — 43; 79; 104; 61 participants
N/A N=134 Vestibular Consequences of Blast-related Mild Traumatic Brain Injury (TBI)
Dizziness · Brain Injury
Primary: Peripheral Vestibular Function (Vestibulo-ocular Reflex/Semicircular Canal): Caloric Weakness — 8.8; 14.7; 12.3; 7.1 percentage of caloric weakness
Phase 1 N=5 Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability
Dizziness
Primary: Change in Dynamic Gait Index (DGI) From Baseline to 6 Weeks. — 4.3 units on a scale
N/A N=28 Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
Covid19
Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds
N/A N=30 Virtual Environments for Vestibular Rehabilitation
Dizziness Chronic · Vertigo, Peripheral · Fall
Primary: Visual Vertigo Analog Scale (VVAS) — 43.05; 36.84; 31.28; 21.41 score on a scale — p=0.027
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025